AtriCure rises on expanded approval in Europe for its heart device

AtriCure

22/08/2024 15:38

** Shares of AtriCure  ATRC.O  rise 1.5% to $24.36 in
morning trade
    ** Medical device maker says the European approval for its
AtriClip device has been expanded to include patients who are at
high risk for thromboembolism, and require a surgery to block a
part of the heart to stop clots from entering the bloodstream
    ** Thromboembolism is the obstruction of a blood vessel by a
blood clot
    ** AtriClip is a device for the treatment of atrial
fibrillation, a condition characterized by an irregular rhythm
of the heart
    ** YTD, stock down 32.2%

 (Reporting by Puyaan Singh)
 ((Puyaan.Singh@thomsonreuters.com;))